Clinical Trials
The phase III clinical trial of REC603 in China consists of three parts, i.e. the efficacy trial, the immuno-bridging trial in younger-age groups...
August 11, 2022 | News
-Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vacc...
August 09, 2022 | News
Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of ...
August 05, 2022 | News
In global Phase 3 clinical trial, Tigulixostat will be evaluated in 350 adult gout patients with hyperuricemia for safety and efficacy at Month 6 of treatm...
August 04, 2022 | News
This study is to evaluate the safety, tolerability, and pharmacokinetics of the LNK01004 ointment in healthy adults and patients with mild to moderate plaq...
July 29, 2022 | News
Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously d...
July 27, 2022 | News
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide, with up to 14% being classified as SCLC in the U.S.1...
July 22, 2022 | News
As many Korean pharmaceutical manufacturers are currently attempting to develop new drugs for idiopathic pulmonary fibrosis, Daewoong Pharmaceutical's new ...
July 21, 2022 | News
Dr. Shaoliang Chen, Chair of Pulnovo Medical's Scientific Advisory Board and pioneer of the PADN technology, attended the meeting and presented the co...
July 18, 2022 | News
Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announce...
July 14, 2022 | News
ingapore-based SCG Cell Therapy Pte Ltd ("SCG") announced that U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) ...
July 12, 2022 | News
Sobi® announced an exclusive license agreement with ADC Therapeutics SA to develop and commercialise loncastuximab tesirine for use in haematology and ...
July 11, 2022 | News
TLX250-CDx, which has received "Breakthrough Designation" from the U.S. Food and Drug Administration (FDA)1, is being developed as an imaging agent for use...
July 11, 2022 | News
Vaccizone has developed and patented a novel method for delivering antigens and bioactive compounds which can increase the stability and shelf life of comp...
July 07, 2022 | News
Most Read
Bio Jobs
News
Editor Picks